Efficacy of soluble IL-4 receptor for the treatment of adults with asthma.

BACKGROUND IL-4 mediates important proinflammatory functions in asthma, including induction of the IgE isotype switch, increased expression of vascular cell adhesion molecule 1 and promotion of eosinophil transmigration across the endothelium, stimulation of mucus production, and T(H)2 lymphocyte differentiation, leading to release of IL-4, IL-5, IL-9, and IL-13. OBJECTIVE The current study evaluated the therapeutic potential of inhaled recombinant human soluble interleukin-4 receptor (IL-4R) as an IL-4 antagonist. METHODS This study was a randomized, double-blind, placebo-controlled study in 62 subjects involving 12 once weekly nebulizations of 0.75, 1.5, or 3.0 mg of IL-4R or placebo. During screening, subjects documented dependence on inhaled corticosteroids by an exacerbation in asthma induced by one or two 50% dose reductions at 2-week intervals. After restabilization for 2 weeks on the dose above which their asthma flared, inhaled steroids were discontinued, patients were randomized, and study medication was started on day 0. RESULTS IL-4R was well tolerated. Efficacy was demonstrated by a decline in FEV(1) observed in the placebo group (-0.4 L and -13% predicted), which did not occur in the group receiving 3.0 mg of IL-4R (-0.1 L and -2% predicted; P =.05 over the 3-month treatment period). Daily patient-measured morning FEV(1) also demonstrated a significant decline in the placebo group (-0.5 L and -18% predicted), which did not occur in the group receiving 3.0 mg of IL-4R (-0.1 L and -4% predicted; P =.02 over the 3-month treatment period). The efficacy of IL-4R was further confirmed by the absence of increase in asthma symptom scores in the group receiving 3.0 mg of IL-4R (Delta 0.1) compared with that seen in the placebo group (Delta 1.4 over 1 month; P =.07). Study discontinuation for asthma exacerbation was not significantly different between groups (placebo, 56%; 3.0 mg of IL-4R, 47%; P = not significant). CONCLUSION These promising data suggest that IL-4R is safe and effective in the treatment of moderate persistent asthma.

[1]  W. Henderson,et al.  Soluble IL-4 Receptor Inhibits Airway Inflammation Following Allergen Challenge in a Mouse Model of Asthma1 , 2000, The Journal of Immunology.

[2]  L. Borish,et al.  Interleukin-4 receptor in moderate atopic asthma. A phase I/II randomized, placebo-controlled trial. , 1999, American journal of respiratory and critical care medicine.

[3]  D D Donaldson,et al.  Interleukin-13: central mediator of allergic asthma , 1998 .

[4]  D B Corry,et al.  Requirement for IL-13 independently of IL-4 in experimental asthma. , 1998, Science.

[5]  J. Vries.  The role of IL-13 and its receptor in allergy and inflammatory responses , 1998 .

[6]  F. Finkelman,et al.  IL-13, IL-4Ralpha, and Stat6 are required for the expulsion of the gastrointestinal nematode parasite Nippostrongylus brasiliensis. , 1998, Immunity.

[7]  F. Finkelman,et al.  Cytokine regulation of host defense against parasitic gastrointestinal nematodes: lessons from studies with rodent models. , 1997, Annual review of immunology.

[8]  R. Flavell,et al.  A novel role for murine IL-4 in vivo: induction of MUC5AC gene expression and mucin hypersecretion. , 1997, American journal of respiratory cell and molecular biology.

[9]  R. Pawankar,et al.  Nasal mast cells in perennial allergic rhinitics exhibit increased expression of the Fc epsilonRI, CD40L, IL-4, and IL-13, and can induce IgE synthesis in B cells. , 1997, The Journal of clinical investigation.

[10]  P. Foster,et al.  Aeroallergen-induced eosinophilic inflammation, lung damage, and airways hyperreactivity in mice can occur independently of IL-4 and allergen-specific immunoglobulins. , 1997, The Journal of clinical investigation.

[11]  L. Bradley,et al.  Enhanced development of Th2-like primary CD4 effectors in response to sustained exposure to limited rIL-4 in vivo. , 1996, Journal of immunology.

[12]  E. Gelfand,et al.  Prevention of the development of immediate hypersensitivity and airway hyperresponsiveness following in vivo treatment with soluble IL-4 receptor. , 1996, International archives of allergy and immunology.

[13]  John L. Hankinson,et al.  Standardization of Spirometry, 1994 Update. American Thoracic Society. , 1995, American journal of respiratory and critical care medicine.

[14]  C. Bertrand,et al.  Interleukin-4 is required for the induction of lung Th2 mucosal immunity. , 1995, American journal of respiratory cell and molecular biology.

[15]  R. Pauwels,et al.  Importance of interleukin-4 and interleukin-12 in allergen-induced airway changes in mice. , 1995, International archives of allergy and immunology.

[16]  R. Coffman,et al.  IL-13 selectively induces vascular cell adhesion molecule-1 expression in human endothelial cells. , 1995, Journal of immunology.

[17]  E. Gelfand,et al.  Inhibition of allergen-induced IgE and IgG1 production by soluble IL-4 receptor. , 1995, International archives of allergy and immunology.

[18]  S A Goldstein,et al.  Osteoporosis induced in mice by overproduction of interleukin 4. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[19]  Martin Bachmann,et al.  Disruption of the murine IL-4 gene blocks Th2 cytokine responses , 1993, Nature.

[20]  C. Maloney,et al.  Bone metabolism in children with asthma treated with inhaled beclomethasone dipropionate. , 1993, The Journal of pediatrics.

[21]  M. de Carli,et al.  IL-4 and IFN (alpha and gamma) exert opposite regulatory effects on the development of cytolytic potential by Th1 or Th2 human T cell clones. , 1992, Journal of immunology.

[22]  R. Cotran,et al.  Effects of tumor necrosis factor, lipopolysaccharide, and IL-4 on the expression of vascular cell adhesion molecule-1 in vivo. Correlation with CD3+ T cell infiltration. , 1992, Journal of immunology.

[23]  W. Paul,et al.  The presence of interleukin 4 during in vitro priming determines the lymphokine-producing potential of CD4+ T cells from T cell receptor transgenic mice , 1992, The Journal of experimental medicine.

[24]  J. Fehr,et al.  IL-4 controls the selective endothelium-driven transmigration of eosinophils from allergic individuals. , 1992, Journal of immunology.

[25]  C. Hsieh,et al.  Differential regulation of T helper phenotype development by interleukins 4 and 10 in an alpha beta T-cell-receptor transgenic system. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[26]  J. Thèze,et al.  IL-4 plays a dominant role in the differential development of Tho into Th1 and Th2 cells. , 1992, Journal of immunology.

[27]  M. de Carli,et al.  Reciprocal regulatory effects of IFN-gamma and IL-4 on the in vitro development of human Th1 and Th2 clones. , 1992, Journal of immunology.

[28]  F. Luscinskas,et al.  IL-4 induces adherence of human eosinophils and basophils but not neutrophils to endothelium. Association with expression of VCAM-1. , 1992, Journal of immunology.

[29]  G. Guyatt,et al.  Evaluation of impairment of health related quality of life in asthma: development of a questionnaire for use in clinical trials. , 1992, Thorax.

[30]  G. Koch,et al.  The Application of the Principle of Intention–to–Treat to the Analysis of Clinical Trials , 1991 .

[31]  A. Weinberg,et al.  IL-4 directs the development of Th2-like helper effectors. , 1990, Journal of immunology.

[32]  M. Thornhill,et al.  IL-4 increases human endothelial cell adhesiveness for T cells but not for neutrophils. , 1990, Journal of immunology.

[33]  R. Geha,et al.  Human recombinant interleukin 4 induces Fc epsilon R2/CD23 on normal human monocytes , 1988, The Journal of experimental medicine.

[34]  R. Geha,et al.  Clinical and immunologic aspects of the hyperimmunoglobulin E syndrome. , 1988, Hematology/oncology clinics of North America.

[35]  J. Hankinson,et al.  Standardization of spirometry. , 1988, The American review of respiratory disease.

[36]  W. Paul,et al.  Differential regulation of IgG1 and IgE synthesis by interleukin 4 , 1988, The Journal of experimental medicine.

[37]  K. Arai,et al.  Human recombinant interleukin 4 induces Fc epsilon receptors (CD23) on normal human B lymphocytes , 1987, The Journal of experimental medicine.

[38]  W. Paul,et al.  Suppression of in vivo polyclonal IgE responses by monoclonal antibody to the lymphokine B-cell stimulatory factor 1. , 1986, Proceedings of the National Academy of Sciences of the United States of America.

[39]  Weiner Dl.  NONLIN84/PCNONLIN: software for the statistical analysis of nonlinear models. , 1986 .

[40]  R. Coffman,et al.  B cell stimulatory factor-1 enhances the IgE response of lipopolysaccharide-activated B cells. , 1986, Journal of immunology.

[41]  R. Coffman,et al.  A T cell activity that enhances polyclonal IgE production and its inhibition by interferon-gamma. , 1986, Journal of immunology.

[42]  P. W. Bowman,et al.  PHS Public Health Service , 1963 .